HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Haynie, T. P. Articles by Glenn, H. J. Search for Related Content PubMed PubMed Citation Articles by Haynie, T. P. Articles by Glenn, H. J.

The Kinetics of ^99mTc-, ^113mIn-, and ¹⁶⁹Yb-DTPA Compounds in Brain Sarcoma and Kidneys of Mice

The University of Texas at Houston, M. D. Anderson Hospital and Tumor Institute, and The University of Texas at Houston Graduate School of Biomedical Sciences, Houston, Texas

Correspondence: For reprints contact: Thomas P. Haynie, 6723 Bertner, Houston, Tex. 77025.

ABSTRACT

Studies of experimental tumor localization and renal clearance in mice of DTPA preparations labeled with ^99mTc, ^113mIn, and ¹⁶⁹Yb revealed significant differences between the technetium compound and the indium and ytterbium chelates. These were (A) slower renal clearance and (B) higher radionucide tumor content and tumor-to-brain ratios with the technetium compound. These findings support the contention that the Tc-DTPA preparation used in these experiments is not a true chelate and is biologically more like the iron-ascorbic acid complex of technetium than a DTPA chelate. The results also suggest that there may be some advantages for this technetium compound for tumor localization studies over the true DTPA chelates.